Belatacept as immunosuppression in patient with recurrence of hemolytic uremic syndrome after renal transplantation

Transplantation

Volumn 87, Issue 12, 2009, Pages 1901-1903

  Midtvedt, Karsten ^a   Bitter, Jan ^b   Dorje, Christina ^a   Bjorneklett, Rune ^c   Holdaas, Hallvard ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Vest Agder Sentralsykehus ^*  (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; BELATACEPT; CREATININE; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADULT; ARTHRALGIA; CASE REPORT; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG WITHDRAWAL; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LETTER; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; PROTEINURIA; RECURRENT DISEASE; SKIN BURNING SENSATION; UNSPECIFIED SIDE EFFECT;

ADULT; CREATININE; FEMALE; HEMOGLOBINS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; L-LACTATE DEHYDROGENASE; PLATELET COUNT; RECURRENCE;

EID: 67649607421     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181a991ca     Document Type: Letter

References (10)

1. Artz MA, Steenbergen EJ, Hoitsma AJ, et al. Renal transplantation in patients with hemolytic uremic syndrome: High rate of recurrence and increased incidence of acute rejections. Transplantation 2003; 76: 821.
2. Oyen O, Strom EH, Midtvedt K, et al. Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome. Am J Transplant 2006; 6: 412.
3. Ducloux D, Rebibou JM, Semhoun-Ducloux S, et al. Recurrence of hemolytic-uremic syndrome in renal transplant recipients:Ametaanalysis. Transplantation 1998; 65: 1405.
4. Abraham KA, Little MA, Dorman AM, et al. Hemolytic-uremic syndrome in association with both cyclosporine and tacrolimus. Transpl Int 2000; 13: 443.
5. Barone GW, Gurley BJ, bul-Ezz SR, et al. Sirolimus-induced thrombotic microangiopathy in a renal transplant recipient. Am J Kidney Dis 2003; 42: 202.
6. Florman S, Benchimol C, Lieberman K, et al. Fulminant recurrence of atypical hemolytic uremic syndrome during a calcineurin inhibitor-free immunosuppression regimen. Pediatr Transplant 2002; 6: 352.
7. Reynolds JC, Agodoa LY, Yuan CM, et al. Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis 2003; 42: 1058.
8. Bresin E, Daina E, Noris M, et al. Outcome of renal transplantation in patients with nonshiga toxin-associated hemolytic uremic syndrome: Prognostic significance of genetic background. Clin JAmSoc Nephrol 2006; 1: 88.
9. Wiener Y, Nakhleh RE, Lee MW, et al. Prognostic factors and early resumption of cyclosporine A in renal allograft recipients with thrombotic microangiopathy and hemolytic uremic syndrome. Clin Transplant 1997; 11: 157.
10. Ashman N, Chapagain A, Dobbie H, et al. Belatacept as maintenance immunosuppression for postrenal transplantation de novo drug-induced thrombotic microangiopathy. Am J Transplant 2009; 9: 424.